ALSO NOTED: Acorda gains $10M in funds; Supreme Court debates patent law; and much more...

> Acorda Therapeutics has amended its deal with Paul Capital Healthcare to gain up to $10 million in additional funds. Release [1]

> Pain Therapeutics says its painkiller PTI-202 successfully completed a Phase I trial. Release [2]

> The U.S. Supreme Court debated a critical test of U.S. patent law in a case that has broad implications [3] for the biotech industry. Report [4]

> While citing progress in containing bird flu in Asia, the UN's bird flu chief says it will need another $1.3 billion to fight the spread of H5N1 in Africa and other countries. Report [5]

> Novartis is mulling over the sale of the baby food company Gerber. It's already in talks to sell a medical nutrition subsidiary to Nestle. Report [6] (WSJ sub. req.)

> Auxilium Pharmaceuticals has amended its manufacturing agreement with UK-based Cobra Biologics. Under the amended agreement, Cobra will complete only one BLA batch of the active ingredient for AA4500, its injectable enzyme. Release [7]

> Arena Pharmaceuticals plans to sell eight million shares in a public offering. Report [8]

> Zila says it has completed its transition to a cancer detection company. Release [9]

And Finally… Confronted by the embarrassing scandal [10] surrounding the fraudulent Korean stem cell study in 2004, Science magazine has devised new methods to scrutinize research findings. Article [11]